Ironwood Pharmaceuticals, Inc.
IRWD
$1.44
-$0.01-0.69%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 378.42M | 400.57M | 413.55M | 442.74M | 432.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 378.42M | 400.57M | 413.55M | 442.74M | 432.38M |
| Cost of Revenue | 125.41M | 128.36M | 117.75M | 104.79M | 75.86M |
| Gross Profit | 253.01M | 272.20M | 295.80M | 337.95M | 356.53M |
| SG&A Expenses | 157.25M | 153.48M | 148.50M | 142.01M | 123.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 282.66M | 281.85M | 266.26M | 246.80M | 199.29M |
| Operating Income | 95.76M | 118.72M | 147.30M | 195.94M | 233.09M |
| Income Before Tax | 71.56M | 86.13M | -1.01B | -948.07M | -906.16M |
| Income Tax Expenses | 74.68M | 78.94M | 72.46M | 83.49M | 74.78M |
| Earnings from Continuing Operations | -3.12 | 7.18 | -1.08K | -1.03K | -980.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 658.00K | 2.03M | 29.32M | 29.32M | 28.66M |
| Net Income | -2.46M | 9.21M | -1.05B | -1.00B | -952.29M |
| EBIT | 95.76M | 118.72M | 147.30M | 195.94M | 233.09M |
| EBITDA | 97.80M | 120.36M | 149.10M | 197.51M | 234.49M |
| EPS Basic | -0.02 | 0.06 | -6.77 | -6.45 | -6.12 |
| Normalized Basic EPS | 0.27 | 0.38 | 0.72 | 0.97 | 1.16 |
| EPS Diluted | -0.02 | 0.04 | -6.79 | -6.51 | -6.23 |
| Normalized Diluted EPS | 0.27 | 0.35 | 0.69 | 0.89 | 1.04 |
| Average Basic Shares Outstanding | 632.43M | 628.61M | 624.97M | 621.72M | 619.04M |
| Average Diluted Shares Outstanding | 632.96M | 659.62M | 655.97M | 684.95M | 714.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
